Alan Gold
About Alan Gold
Alan Gold, age 81, is a long-tenured director of Elite Health Systems Inc. (EHSI), serving on the board since its formation in 1993; he served as President and Chairman from 1993 to July 2024 and previously led Global Health Systems (GHS) and held executive roles in healthcare automation at Libra Group and Health Management Systems . His biography emphasizes decades of operational leadership in healthcare IT and related ventures, but does not disclose formal education details .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Elite Health Systems Inc. | Director; President & Chairman | Director since 1993; President & Chairman 1993–Jul 2024 | Led corporate oversight as Chair and PEO for decades |
| Global Health Systems (GHS) | President; Director | President 1983–May 1999; Director through Nov 1999 | Founding leadership; predecessor to GHS |
| Global Health Systems predecessor (Global Health Systems) | Founder; President | Since formation in July 1983 | Built healthcare automation capabilities |
| Libra Group (Global Health Foundation; Libra Research; Libra Technology) | Executive VP, President of related units | 1981–1983 | Senior roles across healthcare automation units |
| Health Management Systems | Employee | Jul 1997–Mar 1998 | Operational role in health IT |
External Roles
No other current public company directorships are disclosed in Mr. Gold’s proxy biography .
Board Governance
| Item | Detail |
|---|---|
| Board meetings (FY2024) | 7 meetings; directors attended at least 75% of board and committee meetings during their service periods |
| Audit Committee | Members: Leimkuhler, St. Lawrence, Gold |
| Audit Committee independence | Board determined Leimkuhler and St. Lawrence are “independent” under Rule 10A-3 and Nasdaq; no such determination for Gold |
| Audit Committee meetings | Met once since establishment in November 2024; charter available on company website |
| Special Committee (PSS acquisition) | Board appointed Leimkuhler, St. Lawrence, and Gold to a “special committee of disinterested and independent members” to consider a related-party acquisition of PSS; ran a multi-step process April–September 2025 |
| Lead Independent Director | William St. Lawrence designated lead director Aug 6, 2025 |
- The proxy explicitly designates only two audit members as independent, excluding Gold, yet describes the PSS special committee as “disinterested and independent” despite including Gold — a governance consistency risk to monitor .
- The Audit Committee is responsible for related-party transaction review, relevant given the PSS acquisition’s insider ties .
Fixed Compensation
Mr. Gold’s disclosed compensation relates to executive pay during his tenure as President/Chairman; directors who are officers do not receive additional board compensation .
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Salary ($) | 188,000 | 125,000 | 25,000 |
| Bonus ($) | — | — | — |
| Option Awards ($) | — | — | — |
| Non-Equity Incentive ($) | — | — | — |
| All Other Compensation ($) | — | — | — |
| Total ($) | 188,000 | 125,000 | 25,000 |
- Directors who are officers receive no additional board pay; the proxy lists director compensation detail for other directors (e.g., St. Lawrence, Leimkuhler) but does not disclose any director retainer or equity grants for Mr. Gold for 2024–2025 .
Performance Compensation
The company states it did not utilize TSR or net loss in executive compensation, and historically provided base salary or stock in lieu of cash with no options/bonus; it expects to implement performance-based incentives (options/RSUs) in the future . Pay-versus-performance disclosure shows CAP for PEO #1 (Alan Gold) prior to the transition to PEO #2 (Dr. Jeereddi).
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Compensation Actually Paid (CAP) to Alan Gold ($) | 188,000 | 125,000 | 25,000 |
| Value of $100 Investment Based on TSR ($) | 347.83 | 195.65 | 47.83 |
| Net Income (Loss) ($000s) | (127) | (816) | (2,055) |
- Narrative: From 2021–2022 TSR decreased and CAP for Gold declined 33% (from $188k to $125k); by 2024 TSR increased from 2022 to 2024 while CAP fell further to $25k as PEO responsibilities shifted mid-2024 .
Other Directorships & Interlocks
- No current public company directorships or disclosed interlocks for Alan Gold; biography lists prior executive roles but no concurrent outside public boards .
Expertise & Qualifications
- Founder/operator with multi-decade experience in healthcare automation and IT, including leading GHS and roles at Libra Group units; deep operational oversight experience from long tenure as EHSI President/Chairman .
- The Audit Committee does not designate any member (including Gold) as an “audit committee financial expert” under SEC rules; members meet Nasdaq financial literacy requirements .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| Alan Gold | 1,140,246 | 5.2% | Held jointly with spouse as joint tenants with rights of survivorship |
| Options/Warrants (exercisable within 60 days) | None outstanding company-wide at filing | — | “No such options exist at the time of filing” |
- Strong “skin in the game” via >5% ownership, aligned with shareholder outcomes .
Governance Assessment
- Strengths: Extremely long board/service tenure, deep domain experience, and significant ownership (5.2%) supporting alignment with shareholders .
- Weaknesses/risks:
- Audit Committee independence: Board only designated Leimkuhler and St. Lawrence as independent; Gold not designated independent under Rule 10A-3, reducing committee independence optics .
- Special Committee characterization inconsistency: The PSS related-party transaction committee is described as “disinterested and independent” yet includes Gold, who is not designated independent for the Audit Committee — a governance quality concern .
- Related-party concentration: CEO/Chair (Jeereddi) and affiliates expected to own ~14.3% post-acquisition, potentially limiting other shareholders’ influence and compounding insider control dynamics .
- Board process cadence: Audit Committee met only once since establishment in Nov 2024; ensure adequacy of financial oversight given the related-party transaction activity and integration risks .
- Red flags:
- Inconsistent independence labeling across committees for a related-party transaction → potential procedural weakness in conflict management .
- Elevated insider concentration post-acquisition → potential entrenchment risk .
- Limited Audit Committee meeting frequency to date amid complex transaction/integration risks .
Overall, Mr. Gold’s significant ownership and long operational background are positives for alignment and institutional memory, but independence limitations and committee designation inconsistencies warrant heightened scrutiny of related-party oversight and audit rigor .